A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)
Crossref DOI link: https://doi.org/10.1007/s10147-015-0895-3
Published Online: 2015-09-04
Published Print: 2016-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ogata, Yutaka
,
Shimokawa, Mototsugu
Tanaka, Takaho
Emi, Yasunori
Oki, Eiji
Saeki, Hiroshi
Sadanaga, Noriaki
Kusumoto, Tetsuya
Touyama, Tetsuo
Kimura, Masami
Baba, Hideo
Akagi, Yoshito
Shirouzu, Kazuo
Maehara, Yoshihiko
License valid from 2015-09-04